Compare Bristol-Myers Squibb Co (BMY) vs KLA Corp. (KLAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs KLA Corp. — how do they compare? Bristol-Myers Squibb Co trades at $58.7 (market cap $116.30B), while KLA Corp. trades at $225.36 (market cap $300.93B). The key difference: KLA Corp. is far larger — about 2.6× Bristol-Myers Squibb Co's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | KLAC | |
|---|---|---|
Market Cap | $116.30B | $300.93B |
Sector | Health | Technology |
52-Week High | $62.37 | $301.71 |
52-Week Low | $42.60 | $84.39 |
Enterprise Value | $152.24B | $302.11B |
Dividend Yield | 4.42% | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
KLA Corporation (KLAC) trades at $222.25, down 4.0% on the day, with technical indicators showing a neutral to bearish short-term bias. The stock exhibits strong fundamentals with revenue growth to $12.16B in 2025 and net income of $4.06B, though valuation multiples remain elevated. Recent corporate actions include a 1:10 stock split effective June 12, 2026, and a $2.30 dividend paid in June 2026.
Outlook remains supported by AI-driven semiconductor equipment demand and consistent earnings beats, but rich valuation and competitive pressures pose risks. Analyst consensus is bullish with a $239.86 price target, suggesting potential upside from current levels if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →
